Case Studies

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Resource Types

A Complete Nonclinical GLP Tox Study Package for a Successful IND Submission in Six Months
See how Syngene delivered a complete GLP tox study package for ART26.12 and supported IND submission in six months. Read the case study.
Read
Read
Neutralizing antibody assay for a fully human PD-1 blocking monoclonal antibody
Learn how Syngene’s PD-1 neutralizing antibody bioassay reduced donor variability and drug interference for immunogenicity assessment. Read the full case study today.
Read
Read
Immunogenicity assay for an RNAi therapeutic (small interfering RNA) on the MSD platform
Syngene’s MSD-based ADA assay enabled sensitive, drug-tolerant immunogenicity assessment for a clinical siRNA therapeutic in regulated studies. Learn more.
Read
Read
Pharmacokinetics-focused bioanalysis for a half-life extended bispecific antibody in oncology
See how Syngene used MSD platform pharmacokinetics and immunogenicity assays to de-risk a half-life extended bispecific antibody in oncology. Explore the case study.
Read
Read
Bioanalysis for a fit-for-purpose PK assay for a novel bispecific nanobody
Discover how Syngene developed a fit-for-purpose PK assay for a novel bispecific nanobody, achieving a 1.00 to 1000 ng/mL dynamic range and a low 1%...
Read
Read
Automation driven optimization of liver microsomal stability (LMS) assays for ADME studies
Syngene enhances ADME studies with automated liver microsomal stability assays, improving DMPK precision, boosting throughput, and accelerating ADME screening workflows.
Read
Read
Hybrid, device-enabled IPF cough trial for a Swedish sponsor— integrated formulation-to-site execution by Syngene
In this case study, you would learn how Syngene enabled a hybrid, device-based IPF cough trial in India for a clinical-stage pharma company—delivering seamless formulation-to-site...
Read
Read
Enhancing Patient Compliance: Developing an ExtendedRelease Anti-Epileptic Drug
The current immediate-release (IR) tablet formulation for epilepsy1 , available in Europe, requires multiple doses due to the drug’s short half-life, making it inconvenient for...
Read
Read
Syngene Enhances Bispecific Antibody Production
The GEM-DIMER™ platform is a proprietary technology developed by Hinge Bio. This technology allows the production of antibodies with enhanced multivalency and multispecificity, enabling the...
Read
Read
Pharmaceutical Development of a Broad-Spectrum Antibacterial Candidate for Multidrug-Resistant Infections
The World Health Organization (WHO) has identified antimicrobial resistance (AMR) as one of the top ten global public health threats. Despite concerted global efforts, AMR...
Read
Read